Subscribe
Logo smallSearch
AOTMiT

The Transparency Board will evaluate medications for migraine and lymphoma

MedExpress Team

Medexpress

Published Jan. 20, 2022 08:12

The Transparency Board will evaluate medications for migraine and lymphoma - Header image
Źródło: AOTMiT

The agenda includes:
Preparation of positions on the evaluation of the drug Emgality (galcanezumabum) under the drug program: "Prophylactic treatment of patients with chronic migraine (ICD-10: G43)".
Preparation of an opinion on the reimbursement of drugs containing the active substance oxaliplatinum in the following indications:
• C81 Malignant Hodgkin's disease [Hodgkin's disease] (C.81.0 Lymphocyte predominance; C.81.1 Nodular sclerosis; C.81.2 Mixed cell form; C.81.3 Lymphocyte atrophy; C.81.7 Other malignant Hodgkin's disease; C.81.9 Malignant Hodgki...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Najciekawsze oferty pracy (przewiń)